Harpreet Kaur
Endocrinology, Diabetes & Metabolism · Mason City, IANPI 1427214170
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AstraZeneca at 29.1% of the total. Reporting peaked in 2019 at $467 and has fallen 96.7% since, to $15 in 2025.
Across 45 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$222
- Insulet Corporation$167
- Abbott$68
- Johnson & Johnson$55
- Sanofi-aventis U.S. LLC$49
- Novo Nordisk$45
- plus $157 from 8 others
What the payments were for
- Food & beverage$75899%
- Education$61%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $222 |
| Insulet Corporation | 10 | $167 |
| Abbott | 3 | $68 |
| Johnson & Johnson | 4 | $55 |
| Sanofi-aventis U.S. LLC | 4 | $49 |
| Novo Nordisk | 3 | $45 |
| Biohaven Pharmaceuticals, Inc. | 3 | $42 |
| Lilly USA, LLC | 2 | $29 |
| Medtronic(2 entities) | 2 | $24 |
| Sequel Med Tech, LLC | 1 | $15 |
| Corcept Therapeutics | 1 | $13 |
| Bayer | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$119
How this compares
$764 in reported general payments places this provider in the 60th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.
See all endocrinology, diabetes & metabolism providers in Iowa →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 294 | $341,335 |
| FarxigaDapagliflozin Propanediol | 173 | $151,442 |
| MounjaroTirzepatide | 134 | $143,158 |
| TrulicityDulaglutide | 97 | $100,708 |
| JardianceEmpagliflozin | 71 | $72,304 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 56 | $54,100 |
| Humalog Kwikpen U-200Insulin Lispro | 18 | $40,334 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $38,928 |
| Bydureon BciseExenatide Microspheres | 30 | $35,857 |
| Victoza 3-PakLiraglutide | 25 | $28,857 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 80 | $27,866 |
| JanuviaSitagliptin Phosphate | 18 | $24,455 |
| Novolog FlexpenInsulin Aspart | 96 | $23,674 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $20,545 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $17,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $45 | $341,335294 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $29 | $249,893259 claims |
| AstraZenecaFarxiga | $222 | $151,442173 claims |
| Boehringer IngelheimJardiance | $11 | $72,30471 claims |
| Sanofi-aventis U.S. LLCLantus | $49 | $1,23713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.
Other endocrinology, diabetes & metabolism in Mason City
- Mary FigaroDavenport$73K
- Ayotunde DokunIowa City$31K
- Anuj BhargavaDes Moines$30K
- Marcelo CorreiaIowa City$10K
- Thomas OdorisioIowa City$7K
- Teck KhooDes Moines$6K
- Rami AlmokayyadAmes$3K
- Amie OgunsakinIowa City$2K
- Fnu DeepikaWaterloo$2K
- Joseph DillonIowa City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.